Risk factors associated with an increase in the size of ground-glass lung nodules on chest computed tomography

Hee-Young Yoon1, Ji-Yun Bae1, Yookyung Kim2, Sung Shin Shim2, Sojung Park1, So-Young Park1, Soo Jung Kim1, Yon Ju Ryu1, Jung Hyun Chang1 & Jin Hwa Lee

1 Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea
2 Department of Radiology, College of Medicine, Ewha Womans University, Seoul, Korea

Abstract

Background: The detection rate of ground-glass nodules (GGNs) in the lung has increased with the increased use of low-dose computed tomography (CT) of the chest for cancer screening; however, limited data is available on the natural history, follow-up, and treatment of GGNs. The aim of this study was to identify factors associated with an increase in the size of GGNs.

Methods: A total of 338 patients (mean ages, 59.8 years; males, 35.5%) with 689 nodules who underwent chest CT at our institute between June 2004 and February 2014 were included in this study. The cut-off date of follow-up was August 2018. We analyzed the size, solidity, number, and margins of the nodules compared with their appearance on previous chest CT images. The Cox proportional hazard model was used to identify risk factors associated with nodule growth.

Results: The median follow-up period was 21.8 months. Of the 338 patients, 38.5% had a history of malignancy, including lung cancer (8.9%). Among the 689 nodules, the median size of the lesions was 6.0 mm (IQR, 5–8 mm), and the proportion of nodules with size ≥10 mm and multiplicity was 17.1% and 66.3%, respectively. Compared to the nodules without an increase in size, the 79 nodules with an increase in size during the follow-up period were initially larger (growth group, 7.0 mm vs. non-growth group, 6.0 mm; \( P = 0.027 \)), more likely to have a size ≥10 mm (26.6% vs. 15.9%; \( P = 0.018 \)), and had less frequent multiplicity (54.4% vs. 67.9%, \( P = 0.028 \)). In the multivariate analysis, nodule size ≥10 mm (hazard ratio [HR], 2.044; \( P = 0.005 \)), a patient history of lung cancer (HR: 2.190, \( P = 0.006 \)), and solitary nodule (HR: 2.499, \( P < 0.001 \)) were independent risk factors for nodule growth.

Conclusion: Careful follow-up of GGNs is warranted in patients with a history of malignancy, a large, or a solitary nodule.
preservation of the bronchial and vascular margins. Newly-detected GGNs reportedly occur in 0.7% (485/64 677) of the screened population per year, resulting in the clinical diagnosis of various benign and malignant conditions.10 Although GGNs may disappear or decrease in size by 50% within threemonths, those that persist longer than threemonths are more likely to be malignant or premalignant lesions, such as atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS).11 In particular, mixed GGNs (those containing a solid portion) have a high likelihood of malignancy.11-13 However, those GGNs that remain unchanged in size over time are much less likely to be malignant.14,15 While observation may be an appropriate approach for some GGNs, it is important to identify rapidly progressing GGNs for biopsy. In addition, lung cancer derived from slow growing GGNs does not significantly affect an individual’s death,13,16 while aggressive treatment such as surgical resection should be considered for rapidly growing GGNs. Although several studies have previously reported the risk factors associated with an increase in GGN size,12,17-21 the sample sizes were small and the follow-up periods relatively short. The aim of this study was to identify factors associated with an increase in the size of newly-detected GGNs in a large study population with a long follow-up period.

Methods

Study population

Five-hundred and fourteen patients with 916 GGNs detected on chest CT were initially screened at Ewha Womans University Mokdong Hospital (Fig 1) between June 2004 and February 2014. A total of 338 patients with 689 GGNs who were available for follow-up chest CT and did not undergo lung resection of the GGNs were included in our study. Patients without follow-up data for GGNs were excluded due to: (i) resected GGNs (n = 3) immediately after the GGN detection, and (ii) follow-up loss (n = 173). A GGN was defined as a circumscribed area of ground-glass opacity with preservation of the bronchial and vascular margins. All subjects were divided into growth and non-growth groups according to whether the size of GGN increased. Informed consent was waived due to the retrospective study design, and this study was approved by the institutional review board of Ewha Womans University Medical Center (EUMC-2019-02-001).

Study design and radiological finding evaluation

The data on demographics, medical history, and radiological findings at the time of first GGN detection were retrospectively obtained through medical charts. Overall cancer history, which was defined as a diagnosis of cancer before our study enrollment and lung cancer history, were analyzed separately from overall cancer history. Underlying lung disease was a radiologic abnormal finding at time of initial chest CT. Chest CT scans included images of routine enhanced CT, high-resolution CT, and low-dose CT with slice thickness of 3 mm (from 2004 to 2012) or 2 mm (from 2013 to 2018). The characteristics of the GGNs (size, number, margin type, and solidity) were collected through review of the CT scan from the time of first GGN detection. The nodule size (in mm) was defined as the longest diameter, measured with electronic calipers. The GGNs were compared by dividing them into two groups based on their sizes (equal to, or larger than, 10 mm, or smaller than 10 mm), number (single or multiple), margin (irregular or regular, ill-defined or well-defined), and solidity (presence or absence). A GGN with an irregular margin was defined as a GGN without a smooth border. A GGN with an ill-defined margin was defined as a GGN where it is difficult to determine the boundary line. The characteristics of the GGNs were interpreted by two experienced thoracic radiologists by consensus in cases of disagreement.

The GGN was followed-up at intervals of 3–12 months under the Fleischner Society recommendation, and modified according to an individual’s past history.22 We reviewed the follow-up chest CT images obtained after the first image showing GGN detection to investigate the time of the changes in radiological features (namely, increase in size, number, solidity, and margin type) from enrollment to August 2018. The follow-up time for a nodule with increasing size was defined as the period between the date...
of the first appearance of the nodule on chest CT and the date of the CT showing a size increase, while that for a nodule with no change in size was defined as the period between the initial detection of the GGN to the last follow-up chest CT.

**Statistical analysis**

Continuous variables were expressed as mean ± standard deviation (SD) or median (interquartile range, IQR). Categorical variables were presented as number (%). For comparison between two groups, Student’s t-test or the Mann Whitney U test was used for continuous variables and the Chi-square test or Fisher exact test was used for categorical variables. Survival rates with 95% confidence intervals (CI) were analyzed using the Kaplan-Meier method, and the differences between groups were compared with the use of the log-rank test. The risk factors for increasing size of GGNs were identified using Cox proportional regression analysis and expressed as a hazard ratio (HR) with 95% CI. Covariates with P < 0.1 on univariate analysis were included in the multivariate analysis. A P-value <0.05 was considered significant (two-tailed). All statistical analysis was performed using SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).

**Results**

**Baseline demographics**

The mean age of the 338 patients with GGNs (Fig 1) was 59.8 years, 35.5% were male, and 10.8% were ever-smokers (Table 1). One-hundred-thirty patients (38.5%) had a history of cancer, including lung cancer (8.9%) and breast cancer (7.7%). The most common underlying lung disease was lung cancer (12.4%), followed by bronchiectasis (11.2%) and pneumonia (7.5%).

**Radiological features of the GGNs**

The median size of the 689 GGNs at initial CT scans was 6.0 mm (IQR, 5.0–8.0 mm) (Table 2); 17.1% were larger than 10 mm, 66.3% were multiple GGNs, 3.6% contained the solid portion, and 9.3%, and 0.8% had ill-defined and irregular margins, respectively. During the follow-up period (median, 21.8 months; IQR, 6.1–54.9 months), 79 GGNs (11.5%) increased in size, 61 (8.9%) revealed development of multiplicity, and 26 (3.8%) acquired new solid portions.

| Table 1 Baseline characteristics of patients with ground-glass nodules |
|------------------------------|-------------------|
| Characteristics              | Number            |
| Age, years                   | 59.8 ± 11.6       |
| Male sex                     | 120 (35.5)        |
| Ever smoker                  | 26 (240) (10.8%)  |
| Smoking amount, pack-years   | 22.3 ± 16.3       |
| History of malignancy        | 130 (38.5)        |
| Lung cancer                  | 30 (8.9)          |
| Breast cancer                | 26 (7.7)          |
| Thyroid cancer               | 18 (5.3)          |
| Lymphoma                     | 12 (3.6)          |
| Underlying lung diseases     |                   |
| Lung cancer                  | 42 (12.4)         |
| Bronchiectasis               | 38 (11.2)         |
| Pneumonia                    | 22 (6.5)          |
| Tuberculosis sequelae        | 21 (6.2)          |
| Emphysema                    | 14 (4.1)          |

Data are presented as mean ± SD or number (%), unless otherwise indicated.

**Comparison of baseline patient characteristics and radiological features between GGNs with and without size increase**

Seventy-nine GGNs (11.5%) in 55 patients (16.3%) showed an increase in size during the follow-up period (Fig 1). Compared to the patients whose GGNs did not increase in size, the 55 patients with growing GGNs more often had a history of cancer (growth group, 58.2% vs. non-growth group, 34.6%, P = 0.001), including lung (20.0% vs. 6.7%, P = 0.004) and thyroid cancer (12.7% vs. 3.9%, P = 0.015). In addition, patients with GGN growth were more likely to

| Table 2 Radiologic characteristics of ground glass nodules at initial chest CT scans |
|------------------------------|-------------------|
| Characteristics              | Number            |
| Lesion size, mm              | 6.0 (5.0–8.0)     |
| Longest diameter ≥ 10 mm     | 118 (17.1)        |
| Multiple GGN                 | 457 (66.3)        |
| Ill-defined margin            | 64 (9.3)          |
| Irregular margin              | 70 (8.2)          |
| Presence of internal solid portion | 25 (3.6)   |
| Changes during follow-up     |                   |
| Increase in size             | 79 (11.5)         |
| Multiplicity                 | 61 (8.9)          |
| Solid portion                 | 26 (3.8)          |
| Margin                       | 10 (1.0)          |
| Median follow-up duration, months | 21.8 (6.1–54.9) |

Data are presented as median (IQR) or number (%), unless otherwise indicated. GGN, ground glass nodule; IQR, interquartile range.
Table 3 Comparison of baseline characteristics between patients with increased ground-glass nodules and those without

| Characteristics          | Patients with growth | Patients without growth | P-value |
|--------------------------|----------------------|-------------------------|---------|
| Number                   | 55                   | 283                     | 0.494   |
| Age, years               | 60.2 ± 10.7          | 59.7 ± 11.8             | 0.168   |
| Male sex                 | 24(43.6)             | 96(33.9)                | 1.000   |
| Ever smoker              | 4/43(9.4)            | 22/197(11.3)            | 0.705   |
| Smoking, pack-years      | 19.4 ± 14.8          | 22.8 ± 16.9             | 0.001   |
| History of cancer        | 32(58.2)             | 98(34.6)                | 0.001   |
| Lung cancer              | 11(20.0)             | 19(6.7)                 | 0.004   |
| Breast cancer            | 3(5.5)               | 23(8.1)                 | 0.001   |
| Thyroid cancer           | 7(12.7)              | 11(3.9)                 | 0.001   |
| Lymphoma                 | 2(3.6)               | 10(3.5)                 | 1.000   |
| Underlying lung disease  |                      |                         |         |
| Lung cancer              | 12(21.8%)            | 30(10.6%)               | 0.021   |
| Bronchiectasis           | 2(3.6)               | 36(12.7)                | 0.001   |
| Pneumonia                | 1(1.8)               | 21(7.4)                 | 0.004   |
| Tuberculosis sequelae    | 3(5.5)               | 18(6.4)                 | 0.226   |
| Emphysema                | 1(1.8)               | 13(4.6)                 | 0.345   |

Data are presented as mean ± SD or number (%), unless otherwise indicated.

have lung cancer (21.8% vs. 10.6%, P = 0.021) (Table 3). Compared to the non-growing GGNs, the growing GGNs exhibited large initial nodule size (growth group, 7.0 mm vs. non-growth group, 6.0 mm; P = 0.027), less multiplicity (54.4% vs. 67.9%, P = 0.024), and a lower frequency of ill-defined margins (2.5% vs. 10.2%, P = 0.028; Table 4). The proportion of GGNs showing solidity and irregular margins were not different between the growth and non-growth groups.

Risk factors for increases in GGN size

The median time from diagnosis to size increase was 19.7 months (IQR, 5.9–50.1 months). The three- and five-year progression rates were 14.2%, and 18.9%, respectively. There was significantly more progression in GGNs larger than 10 mm than in those smaller than 10 mm (P = 0.002, Fig 2a). Also, size increase occurred less often in multiple GGNs than in solitary GGNs (P < 0.001, Fig 2b). A non-significant trend toward size increase was observed in GGNs with a solid portion compared to those without a solid portion (P = 0.059, Fig 2c). In contrast, the GGNs with ill-defined margins did not significantly differ in progression rate compared with GGNs without ill-defined margins (P = 0.237, Fig 2d).

Univariate Cox analysis demonstrated that history of malignancy, history of lung cancer, larger initial GGN size, size larger than 10 mm, and solitary GGNs were associated with an increase in size (Table 5). On multivariate analysis, which included variables with P < 0.1, history of lung cancer (HR, 2.190; 95% CI, 1.253–3.826; P = 0.006), large size (size ≥10 mm; HR, 2.044; 95% CI, 1.235–3.382; P = 0.005), and a single nodule (HR, 2.499; 95% CI, 1.540–4.057; P < 0.001) were independent predictors for size increasing, while a history of thyroid cancer showed an association trend with size increase (HR, 1.839; 95% CI, 0.972–3.479; P = 0.061) (Table 5).

Fig 2a. Also, size increase occurred less often in multiple GGNs than in solitary GGNs (P < 0.001, Fig 2b). A non-significant trend toward size increase was observed in GGNs with a solid portion compared to those without a solid portion (P = 0.059, Fig 2c). In contrast, the GGNs with ill-defined margins did not significantly differ in progression rate compared with GGNs without ill-defined margins (P = 0.237, Fig 2d).

Univariate Cox analysis demonstrated that history of malignancy, history of lung cancer, larger initial GGN size, size larger than 10 mm, and solitary GGNs were associated with an increase in size (Table 5). On multivariate analysis, which included variables with P < 0.1, history of lung cancer (HR, 2.190; 95% CI, 1.253–3.826; P = 0.006), large size (size ≥10 mm; HR, 2.044; 95% CI, 1.235–3.382; P = 0.005), and a single nodule (HR, 2.499; 95% CI, 1.540–4.057; P < 0.001) were independent predictors for size increasing, while a history of thyroid cancer showed an association trend with size increase (HR, 1.839; 95% CI, 0.972–3.479; P = 0.061) (Table 5).

Discussion

Our study which involved 338 patients with 689 GGNs demonstrated an increase in size in 11.5% of the GGNs, with a median time to size increase of 19.7 months. Patient history of cancer (including lung and thyroid cancer), large nodule size, and solitary GGN were independent risk factors for GGN growth.

In our study, large size at the time of detection was significantly associated with an increase in GGN size; this is in accordance with previous research showing that nodule size is an important prognostic factor. The guidelines from the Fleischner Society 2017 and the British Thoracic Society base the recommended follow-up CT interval and tissue sampling according to the size of nodules and the risk of lung cancer.23,24 In several lung cancer risk prediction models, the lung nodule size is an essential component.25–27 Specifically, several studies have reported that GGNs larger than 10 mm are significantly associated with outcomes.17,18,28–30 A study reported by Lee et al. revealed that in pure GGNs, large size (≥10 mm) was a significant risk factor for size increase (odds ratio [OR], 6.46; 95% CI, 2.7–15.6) in 114 patients with 175 GGNs.18 In addition, Matsuguma et al. in their study involving 98 pure GGNs in patients with a history of lung cancer, observed that nodule size greater than 10 mm was an independent risk factor for nodule growth (HR, 13.7; P = 0.001).28 In a patient cohort in Japan, similar findings were reported by Sato et al. showing that large size (≥10 mm) at initial diagnosis (OR, 43.6; 95% CI, 6.01–998) was associated with nodule growth at 36 months in 78 patients with multiple GGNs (n = 299).17 These results are in accordance with...
Figure 2  Kaplan-Meier curves of increases in ground-glass nodules size according to nodule size (a), multiplicity (b), the presence of a solid portion (c) and ill-defined margin (d).

Table 5  Univariate and multivariate analyses for factors associated with increase in sizes of ground-glass nodules

| Variable                  | Univariate |          |          |          |          | Multivariate |          |          |
|---------------------------|------------|----------|----------|----------|----------|--------------|----------|----------|
|                           | Hazard ratio | 95% confidence interval | P-value | Hazard ratio | 95% confidence interval | P-value |
| Age, years                | 1.012       | 0.993–1.031 | 0.209 |             |             |              |          |          |
| Female                    | 0.714       | 0.457–1.118 | 0.141 |             |             |              |          |          |
| Ever smoker               | 1.354       | 0.618–2.967 | 0.449 |             |             |              |          |          |
| History of malignancy     | 1.923       | 1.218–3.035 | 0.005 |             |             |              |          |          |
| Lung cancer               | 2.782       | 1.652–4.684 | <0.001 | 2.190       | 1.253–3.826 | 0.006        |          |          |
| Thyroid cancer            | 1.647       | 0.945–2.870 | 0.078 | 1.839       | 0.972–3.479 | 0.061        |          |          |
| Pneumonia                 | 0.602       | 0.148–2.456 | 0.480 |             |             |              |          |          |
| Bronchiectasis            | 0.417       | 0.131–1.321 | 0.137 |             |             |              |          |          |
| Tuberculosis              | 1.765       | 0.709–4.394 | 0.222 |             |             |              |          |          |
| Emphysema                 | 0.272       | 0.038–1.954 | 0.195 |             |             |              |          |          |
| Lung cancer               | 1.324       | 0.785–2.232 | 0.292 |             |             |              |          |          |
| Lesion size, mm           | 1.086       | 1.037–1.137 | <0.001 |             |             |              |          |          |
| Longest diameter ≥10 mm   | 2.153       | 1.306–3.548 | 0.003 | 2.044       | 1.235–3.382 | 0.005        |          |          |
| Solitary nodule           | 2.232       | 1.426–3.494 | <0.001 | 2.499       | 1.540–4.057 | <0.001       |          |          |
| Solidity                  | 2.545       | 0.930–6.966 | 0.069 | 2.383       | 0.848–6.702 | 0.100        |          |          |
| Irregular margin          | 0.801       | 0.111–5.774 | 0.826 |             |             |              |          |          |
| Ill-defined margin        | 0.439       | 0.108–1.790 | 0.251 |             |             |              |          |          |
our findings. Therefore, we conclude that GGNs larger than 10 mm at the time of detection may require more aggressive management and short-term follow-up rather than observation. In addition, a history of lung cancer, as shown in our study and others, is a risk factor for GGN growth.\(^\text{12,17,29}\) Therefore in patients with large GGNs and a history of lung cancer, treatment should also be managed aggressively.

According to our study, the presence of a solid portion was not associated with GGN growth, which differs from the results of previous studies.\(^\text{18,20,21,28,29}\) Kim et al. showed that in 92 patients who underwent follow-up chest CT after resection, having a solid portion (OR, 41.8; 95% CI, 7.710–379.6) was associated with increasing GGN size on multivariate analysis\(^\text{31}\); similar findings were reported by Lee et al. (OR for GGN growth, 2.69; 95% CI, 1.11–6.95).\(^\text{18}\) Chang et al. also demonstrated that benign GGNs less frequently had a solid component (benign \(n = 20\), 3.7% vs. malignant \(n = 39\), 26.0%, \(P < 0.001\)) than malignant GGNs in patients with extrapulmonary cancers.\(^\text{33}\) The lack of significance of the presence of a solid portion in our study might be attributed to the diagnostic resection without observation of such nodules due to their high risk of malignancy, precluding confirmation of nodule size increase.\(^\text{3,31}\) Also, the proportion of patients undergoing lung resection after the initial detection of GGNs with a solid portion might be relatively high in our study compared to previous studies, as more knowledge of the association between the presence of a solid portion and malignant potential has accumulated. However, the recent study by Sato et al. showed that a part-solid GGN was only a significant factor for GGN growth in multiple GGNs in the univariate analysis and not in the multivariate analysis,\(^\text{37}\) similar to the association observed in our study.

In our study, single nodules had a higher risk of growth than multiple nodules. It remains controversial whether single or multiple nodules have worse outcomes. The number of lung nodules was negatively associated with the diagnosis of lung cancer (OR, 0.92; 95% CI, 0.82–1.00; \(P = 0.048\)) in 1090 persons (5021 nodules) who underwent screening low-dose chest CT.\(^\text{25}\) In contrast, Kim et al. revealed that multiple pure GGNs (median size, 5 mm) did not show an increase in size during the observation period in 73 patients who underwent lung resection for bronchioalveolar carcinoma.\(^\text{32}\) However, in other reported studies, the number of nodules was not related to an increase in GGN size.\(^\text{20,21,33}\) In our study, it is possible that the large size of the solitary nodules (median, 7 mm [solitary] vs. 6 mm [multiple], \(P < 0.001\)) might have contributed to their elevated risk for growth. The observation by Kim et al. that multiple GGNs were smaller in average size than single GGNs (12 ± 7.9 mm [multiple] vs. 17 ± 8.1 mm [solitary], \(P < 0.001\))\(^\text{34}\) also supports our findings.

We demonstrated that the GGNs progression course was indolent with a median time from GGN detection to growth of 19.7 months. Most type of GGNs identified as adenocarcinoma have lepidic predominant patterns with good prognosis and slow progression.\(^\text{35}\) Takahashi et al. revealed that lepidic growth predominant adenocarcinoma sized 3–5 cm showed excellent prognosis compared with non-lepidic predominant patterns adenocarcinoma.\(^\text{36}\) Araki et al. also reported that lepidic growth adenocarcinoma was less invasive than non-lepidic growth adenocarcinoma on histological examination.\(^\text{37}\) Our study did not perform histological evaluation of increased GGN, but an indolent course of GGNs supported the fact that relatively good prognostic lung cancer such as lepidic growth pattern might be associated with GGNs.

Our study had some limitations. First, because this was a retrospective study, there may have been some errors in comparing the radiological features due to non-uniform CT imaging protocols. In particular, the size of nodule in thicker CT sections may have been underestimated compared to that in thin CT sections. However, a 1 mm difference between the thick and thin sections may not have significantly influenced our result. Second, the volume of the actual three-dimensional nodule may not be reflected because we analyzed the longest diameter of the nodule. Third, the CT scan interval was not constant, so it was limited to accurately detecting when the GGN size increase occurred. Lastly, the follow-up period may have been insufficient to detect the progression of slow-growing cancer, particularly for lepidic adenocarcinoma. Despite these limitations, an advantage of this study was the inclusion of a large number of GGNs. Also, because we targeted GGNs detected in all CTs performed within a specific period, the underlying diseases in the study subjects varied. Thus, we could identify links between clinical characteristics, such as cancer history, and the increases in GGN size.

In conclusion, solitary GGNs which are large in size at initial diagnosis and GGNs in patients with a history of lung cancer were significantly associated with an increase in nodule size. Therefore, GGNs with these characteristics should be examined histologically at the time of detection rather than being observed over a period of time. In addition, considering the median progression time of 19.7 months in our study, at least two years of intensive follow-up may be required for GGNs with a high risk of growth.

**Author contributions**

Jung Hyun Chang was responsible for the conception and design of the study. Jung Hyun Chang provided study materials, patients and administrative support. Hee-Young Yoon, Ji-Yun Bae, and Jung Hyun Chang collected and assembled the data. Hee-Young Yoon, Ji-Yun Bae, Yookyung Kim, and...
Jung Hyun Chang analysed and interpreted the data. All authors were responsible for writing the manuscript and gave their final approval for its publication.

**Acknowledgment**

Not applicable.

**Funding**

This study is supported by the National Research Foundation of Korea Grant funded by the Korean Government (2010-0027945) and Research foundation of EWHA Medical Alumni Association from EWHA Medical Alumni Association.

**Disclosure**

Not declared

Financial Disclose: Not declared.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jamal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68: 394–424.

2. National Lung Screening Trial Research Team, Aberle DR, Adams AM e a et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; 365: 395–409.

3. Infante M, Cavuto S, Lutman FR et al. A randomized study of lung cancer screening with spiral computed tomography: Three-year results from the DANTE trial. *Am J Respir Crit Care Med* 2009; 180: 445–53.

4. Saghir Z, Dirksen A, Ashraf H et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: Status after five annual screening rounds with low-dose CT. *Thorax* 2012; 67: 296–301.

5. Wood DE, Kazerooni EA, Baum SL et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2018; 16: 412–41.

6. Mazzone PJ, Silvestri GA, Patel S et al. Screening for lung cancer: CHEST Guideline and Expert Panel Report. *Chest* 2018; 153: 954–85.

7. Kinsinger LS, Anderson C, Kim J et al. Implementation of lung cancer screening in the Veterans Health Administration. *JAMA Intern Med* 2017; 177: 399–406.

8. Wender R, Fontham ET, Barrera E Jr et al. American Cancer Society lung cancer screening guidelines. *CA Cancer J Clin* 2013; 63: 106–17.

9. Jaklitsch MT, Jacobson FL, Austin JH et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thorac Cardiovasc Surg* 2012; 144: 33–8.

10. Yankelevitz DF, Yip R, Smith JP et al. CT screening for lung cancer: Nonsolid nodules in baseline and annual repeat rounds. *Radiology* 2015; 277: 555–64.

11. Oh YJ, Kwon SY, Yoon HI et al. Clinical significance of a solitary ground-glass opacity (GGO) lesion of the lung detected by chest CT. *Lung Cancer* 2007; 55: 67–73.

12. Cho J, Kim ES, Kim SJ et al. Long-term follow-up of small pulmonary ground-glass nodules stable for 3 years: Implications of the proper follow-up period and risk factors for subsequent growth. *J Thorac Oncol* 2016; 11: 1453–9.

13. Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D, Miettinen OS. CT screening for lung cancer: Frequency and significance of part-solid and nonsolid nodules. *AJR Am J Roentgenol* 2002; 178: 1053–7.

14. Sawada S, Komori E, Nogami Y, Segawa Y, Shinkai T, Yamashita M. Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination. *Lung Cancer* 2009; 65: 176–9.

15. Lee HJ, Goo JM, Lee CH, Yoo C-G, Kim YT, Im J-G. Nodular ground-glass opacities on thin-section CT: Size change during follow-up and pathological results. *Korean J Radiol* 2007; 8: 22–31.

16. Jett JR. Limitations of screening for lung cancer with low-dose spiral computed tomography. *Clin Cancer Res* 2005; 11: 4988s–92s.

17. Sato Y, Fujimoto D, Morimoto T et al. Natural history and clinical characteristics of multiple pulmonary nodules with ground glass opacity. *Respirology* 2017; 22: 1615–21.

18. Lee SW, Leem CS, Kim TJ et al. The long-term course of ground-glass opacities detected on thin-section computed tomography. *Respir Med* 2013; 107: 904–10.

19. Kobayashi Y, Sakao Y, Deshpande GA et al. The association between baseline clinical-radiological characteristics and growth of pulmonary nodules with ground-glass opacity. *Lung Cancer* 2014; 83: 61–6.

20. Park CM, Goo JM, Kim TJ et al. Pulmonary nodular ground-glass opacities in patients with extrapulmonary cancers: What is their clinical significance and how can we determine whether they are malignant or benign lesions? *Chest* 2008; 133: 1402–9.

21. Kim H-S, Lee H-J, Jeon JH et al. Natural history of ground-glass nodules detected on the chest computed tomography scan after major lung resection. *Ann Thorac Surg* 2013; 96: 1952–7.

22. Naidich DP, Bankier AA, MacMahon H et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: A statement from the Fleischner Society. *Radiology* 2013; 266: 304–17.
23 MacMahon H, Naidich DP, Goo JM et al. Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. *Radiology* 2017; 284: 228–43.

24 Callister M, Baldwin D, Akram A et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules: Accredited by NICE. *Thorax* 2015; 70: ii1–ii54.

25 McWilliams A, Tammemagi MC, Mayo JR et al. Probability of cancer in pulmonary nodules detected on first screening CT. *N Engl J Med* 2013; 369: 910–9.

26 Gould MK, Ananth L, Barnett PG. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. *Chest* 2007; 131: 383–8.

27 Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules: Application to small radiologically indeterminate nodules. *Arch Intern Med* 1997; 157: 849–55.

28 Matsuguma H, Mori K, Nakahara R et al. Characteristics of subsolid pulmonary nodules showing growth during follow-up with CT scanning. *Chest* 2013; 143: 436–43.

29 Hiramatsu M, Inagaki T, Inagaki T et al. Pulmonary ground-glass opacity (GGO) lesions-large size and a history of lung cancer are risk factors for growth. *J Thorac Oncol* 2008; 3: 1245–50.

30 Takahashi S, Tanaka N, Okimoto T et al. Long term follow-up for small pure ground-glass nodules: Implications of determining an optimum follow-up period and high-resolution CT findings to predict the growth of nodules. *Jpn J Radiol* 2012; 30: 206–17.

31 Park CM, Goo JM, Lee HJ, Lee CH, Chun EJ, Im J-G. Nodular ground-glass opacity at thin-section CT: Histologic correlation and evaluation of change at follow-up. *Radiographics* 2007; 27: 391–408.

32 Kim HK, Choi YS, Kim J, Shim YM, Lee KS, Kim K. Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma. *J Thorac Oncol* 2010; 5: 206–10.

33 Chang B, Hwang JH, Choi YH et al. Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. *Chest* 2013; 143: 172–8.

34 Kim TJ, Goo JM, Lee KW, Park CM, Lee HJ. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: Comparison with solitary ground-glass opacity nodule. *Lung Cancer* 2009; 64: 171–8.

35 Kim DK, Sim HJ, Kim HR et al. Surgical management of pulmonary adenocarcinoma presenting as a pure ground-glass nodule. *Eur J Cardiothorac Surg* 2014; 46: 632–6.

36 Takahashi Y, Ishii G, Aokage K, Hishida T, Yoshida J, Nagai K. Distinctive histopathological features of lepidic growth predominant node-negative adenocarcinomas 3–5cm in size. *Lung Cancer* 2013; 79: 118–24.

37 Araki K, Kidokoro Y, Hosoya K et al. Excellent prognosis of lepidic-predominant lung adenocarcinoma: Low incidence of lymphatic vessel invasion as a key factor. *Anticancer Res* 2014; 34: 3153–6.